Eiropas Savienība - latviešu - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 un 5.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirīns - hiv infekcijas - pretvīrusu līdzekļi sistēmiskai lietošanai - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.